Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $511.09, generating approximately $4.86 million. Her remaining direct ownership is 324,443 shares, a 2.84% reduction.
- United Therapeutics reported quarterly earnings of $7.27 per share, beating estimates of $6.86, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
- Analysts maintain a favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $646; institutional investors own 94.08% of the company’s shares.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $511.09, for a total value of $4,855,355.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company's stock, valued at approximately $165,819,572.87. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
United Therapeutics Price Performance
Shares of UTHR stock opened at $512.70 on Wednesday. United Therapeutics Corporation has a one year low of $375.61 and a one year high of $609.35. The stock has a fifty day moving average price of $529.27 and a 200 day moving average price of $539.68. The stock has a market cap of $21.99 billion, a P/E ratio of 18.34, a price-to-earnings-growth ratio of 2.55 and a beta of 0.56.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company's quarterly revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the business earned $6.41 earnings per share. Equities research analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current year.
Hedge Funds Weigh In On United Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its stake in United Therapeutics by 55,526.2% during the 2nd quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company's stock worth $18,036,953,000 after acquiring an additional 33,229,108 shares during the last quarter. BlackRock Inc. acquired a new stake in United Therapeutics during the 2nd quarter worth $2,868,735,000. Wellington Management Group LLP lifted its holdings in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares in the last quarter. Jupiter Topco LLC bought a new stake in shares of United Therapeutics in the second quarter worth about $450,140,000. Finally, Norges Bank bought a new stake in shares of United Therapeutics in the fourth quarter worth about $293,418,000. Institutional investors and hedge funds own 94.08% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts have recently commented on UTHR shares. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. TD Cowen reaffirmed a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research report on Thursday, August 6th. Bank of America dropped their target price on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. Finally, Weiss Ratings cut shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research note on Thursday, August 27th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $646.00.
View Our Latest Stock Report on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
